Published in Neurology on May 11, 2010
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
The many faces of tau. Neuron (2011) 2.89
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci (2010) 1.41
Biological heterogeneity in ADNI amnestic mild cognitive impairment. Alzheimers Dement (2014) 1.01
Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett (2010) 1.00
BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis (2011) 0.87
Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. JAMA Neurol (2015) 0.85
Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis (2013) 0.84
Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS One (2013) 0.83
Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. Front Neurol (2015) 0.82
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat (2011) 0.81
Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79
"Is dopamine involved in Alzheimer's disease?". Front Aging Neurosci (2014) 0.79
Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.77
Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm (Vienna) (2010) 0.77
Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res (2016) 0.76
Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. J Alzheimers Dis (2016) 0.76
Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain (2016) 0.75
High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. Alzheimers Res Ther (2016) 0.75
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. J Alzheimers Dis (2016) 0.75
Applying fluid biomarkers to Alzheimer's disease. Am J Physiol Cell Physiol (2017) 0.75
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. J Neural Transm (Vienna) (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Site-directed mutagenesis in photosystem II of the cyanobacterium Synechocystis sp. PCC 6803: Donor D is a tyrosine residue in the D2 protein. Proc Natl Acad Sci U S A (1988) 1.57
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. Diabetologia (2008) 1.50
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6-month exercise intervention. Acta Physiol (Oxf) (2014) 1.45
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatr Scand (2014) 1.43
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer (2000) 1.36
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology (2012) 1.35
Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia (2009) 1.33
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int Psychogeriatr (2009) 1.26
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Pathways to Alzheimer's disease. J Intern Med (2014) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res (2001) 1.19
Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr (1998) 1.18
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.17
Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant (2000) 1.15
Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis (2000) 1.13
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord (2006) 1.13
Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) (2008) 1.12
CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm (Vienna) (2001) 1.11
Neurofilament protein levels in CSF are increased in dementia. Neurology (1999) 1.11
Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord (2001) 1.10
Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand (2001) 1.10
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology (1999) 1.09
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm (Vienna) (2000) 1.09
Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurosci (1998) 1.08
Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol (2007) 1.08
Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett (2000) 1.08
Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines. J Virol (2001) 1.07
Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med (2014) 1.07
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology (2000) 1.07
Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol (2000) 1.06
Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med (1999) 1.06
Blood brain barrier function in vascular dementia. Acta Neurol Scand (1990) 1.06
Vaccinia Gangrenosa with normal humoral antibodies. A case possibly due to deficient cellular immunity treated with N-methylisatin beta-thiosemicarbazone (Compound 33T57, Marboran). Acta Paediatr Scand (1966) 1.05
Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2003) 1.05
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord (2010) 1.04
Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry (2004) 1.04
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging (2009) 1.04
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res (2000) 1.03
Familial ataxic diplegia with deficient cellular immunity. A new clinical entity. Acta Paediatr Scand (1970) 1.02